Table Info

Table 1.

ICIs indications approved by FDA and EMA

Drug	FDA indications	EMA indications
Ipilimumab	Melanoma Non-small cell lung cancer Renal cell carcinoma	Melanoma Non-small cell lung cancer Renal cell carcinoma data
Nivolumab	Melanoma Non-small cell lung cancer Small cell lung cancer Renal cell cancer Classical Hodgkin’s lymphoma Squamous cell of esophagus or head and neck Urothelial cancer Colorectal cancer with microsatellite instability or mismatch-repair deficiency Hepatocellular carcinoma	Melanoma Non-small cell lung cancer Renal cell cancer Classical Hodgkin’s lymphoma Squamous cell of esophagus or head and neck Urothelial cancer
Pembrolizumab	Melanoma Non-small cell lung cancer Squamous cell of the head and neck Classical Hodgkin’s lymphoma Urothelial cancer Gastric cancer Esophageal cancer Cervical cancer Renal cell carcinoma Hepatocellular carcinoma Colorectal cancer with microsatellite instability or mismatch-repair deficiency	Melanoma Non-small cell lung cancer Squamous cell of the head and neck Classical Hodgkin’s lymphoma Urothelial cancer Colorectal cancer with microsatellite instability or mismatch-repair deficiency
Cemiplimab	Cutaneous cell carcinoma	Cutaneous cell carcinoma
Atezolizumab	Urothelial carcinoma Non-small cell lung cancer Small-cell lung cancer Breast cancer Hepatocellular carcinoma	Urothelial carcinoma Non-small cell lung cancer Small-cell lung cancer Breast cancer Hepatocellular carcinoma
Avelumab	Merkel cell carcinoma Urothelial carcinoma Renal Cell carcinoma	Merkel cell carcinoma Urothelial carcinoma Renal cell carcinoma
Durvalumab	Urothelial carcinoma Non-small cell lung cancer	Non-small cell lung cancer

Declarations

Author contributions

DB and CQ contributed conception and wrote the first draft of the manuscript; AB and MM reviewed and supervised original draft; LM contributed to conceptualization, supervision and writing of the final draft. All authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12:738. [DOI]

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68. [DOI] [PubMed]

Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 1987;165:302–19. [DOI] [PubMed] [PMC]

Bean WB. The clonal selection theory of acquired immunity. Arch Intern Med. 1960;105:184–93. [DOI] [PubMed]

Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194:769–79. [DOI] [PubMed] [PMC]

Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992;356:607–9. [DOI] [PubMed]

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10. [DOI] [PubMed]

Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T ceils to stimulation. J Exp Med. 1995;182:459–65. [DOI] [PubMed] [PMC]

Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1:32–42. [DOI] [PubMed]

10.

Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6. [DOI] [PubMed]

11.

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61. [DOI] [PubMed] [PMC]

12.

Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8⁺ T cell activation and cytolysis. Eur J Immunol. 2003;33:3117–26. [DOI] [PubMed]

13.

Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209:1201–17. [DOI] [PubMed] [PMC]

14.

Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2:846–56. [DOI] [PubMed]

15.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. [DOI] [PubMed] [PMC]

16.

Yervoy. European Medicines Agency [Internet]. Amsterdam: The Agency; c1995-2021 [cited 2021 Feb 11]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy

17.

Opdivo. European Medicines Agency [Internet]. Amsterdam: The Agency; c1995-2021 [cited 2021 Feb 11]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo

18.

Keytruda. European Medicines Agency [Internet]. Amsterdam: The Agency; c1995-2021 [cited 2021 Feb 11]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda

19.

Tecentriq. European Medicines Agency [Internet]. Amsterdam: The Agency; c1995-2021 [cited 2021 Feb 11]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq

20.

Imfinzi. European Medicines Agency [Internet]. Amsterdam: The Agency; c1995-2021 [cited 2021 Feb 11]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi

21.

Libtayo. European Medicines Agency [Internet]. Amsterdam: The Agency; c1995-2021 [cited 2021 Feb 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo

22.

Bavencio. European Medicines Agency [Internet]. Amsterdam: The Agency; c1995-2021 [cited 2021 Feb 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio

23.

Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–8. [DOI] [PubMed]

24.

Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11: 141–51. [DOI] [PubMed]

25.

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319–22. [DOI] [PubMed]

26.

Lesokhin AM, Callahan MK, Postow MA, Wolchok JD. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med. 2015;7:280sr1. [DOI] [PubMed]

27.

Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. Target Oncol. 2020;15:449–66. [DOI] [PubMed] [PMC]

28.

Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–64. [DOI] [PubMed]

29.

O’Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21:1712–7. [DOI] [PubMed]

30.

Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681–8. [DOI] [PubMed] [PMC]

31.

Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28:593–8. [DOI] [PubMed] [PMC]

32.

Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009;27:1075–81. [DOI] [PubMed]

33.

Joshi MN, Whitelaw BC, Palomar MTP, Wu Y, Carroll PV. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf). 2016;85:331–9. [DOI] [PubMed]

34.

Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38:e55–7. [DOI] [PubMed] [PMC]

35.

Bluestone JA, Anderson M, Herold KC, Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67:1471–80. [DOI] [PubMed] [PMC]

36.

Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35:709–17. [DOI] [PubMed] [PMC]

37.

Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004;27:478–9. [DOI] [PubMed]

38.

Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology. 2009;218:69–70. [DOI] [PubMed]

39.

Bhatia S, Huber BR, Upton MP, Thompson JA. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother. 2009;32:203–5. [DOI] [PubMed]

40.

Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, et al. Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. Oncologist. 2018;23:874–8. [DOI] [PubMed] [PMC]

41.

Belkhir R, Le Burel S, Dunogeant L, Marabelle A, Hollebecque A, Besse B, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76:1747–50. [DOI] [PubMed]

42.

Arnaud L, Lebrun-Vignes B, Salem JE. Checkpoint inhibitor-associated immune arthritis. Ann Rheum Dis. 2019;78:e68. [DOI] [PubMed]

43.

Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol. 2018;10:1758835918764628. [DOI] [PubMed] [PMC]

44.

Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology. 2017;6:e1344805. [DOI] [PubMed] [PMC]

45.

Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohn’s Colitis. 2016; 10:395–401. [DOI] [PubMed] [PMC]

46.

Messmer M, Upreti S, Tarabishy Y, Mazumder N, Chowdhury R, Yarchoan M, et al. Ipilimumab-induced enteritis without colitis: a new challenge. Case Rep Oncol. 2016;9:705–13. [DOI] [PubMed] [PMC]

47.

Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49. [DOI] [PubMed] [PMC]

48.

Chen JH, Pezhouh MK, Lauwers GY, Masia R. Histopathologic features of colitis due to immunotherapy with Anti-PD-1 antibodies. Am J Surg Pathol. 2017;41:643–54. [DOI] [PubMed]

49.

Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, et al. Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohn’s Colitis. 2017;11:1238–46. [DOI] [PubMed]

50.

Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017;28:2860–5. [DOI] [PubMed]

51.

Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. Melanoma Res. 2018;28:645–7. [DOI] [PubMed]

52.

Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391. [DOI] [PubMed] [PMC]

53.

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368–79. [DOI] [PubMed]

54.

Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018;15:382–96. [DOI] [PubMed]

55.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–7. [DOI] [PubMed]

56.

Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28 Suppl 4:iv119–42. [DOI] [PubMed]

57.

Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management. Am Soc Clin Oncol Educ B. 2018;38:13–9. [DOI]

58.

Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study 11 Medical and Health Sciences 1103 Clinical Sciences. J Immunother Cancer. 2018;6:142. [DOI] [PubMed] [PMC]

59.

Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int J Cancer. 2017;141:1018–28. [DOI] [PubMed]

60.

Chascsa DM, Rakela J. Knowns and unknowns: the safety and efficacy of cancer immunotherapy in chronic liver disease. Curr Hepatol Reports. 2018;17:153–5. [DOI]

61.

Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;35:3815–22. [DOI] [PubMed]

62.

Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018;38:976–87. [DOI] [PubMed]

63.

De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68: 1181–90. [DOI] [PubMed]

64.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. [DOI] [PubMed] [PMC]

65.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33. [DOI] [PubMed] [PMC]

66.

Abu-Sbeih H, Tang T, Ali F, Johnson D, Qiao W, Diab A, et al. The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’ outcomes. J Immunother Precis Oncol. 2018;1:7–18. [DOI]

67.

Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368–76. [DOI] [PubMed]

68.

Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95. [DOI] [PubMed] [PMC]

69.

Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline summary. J Oncol Pract. 2018;14:247–9. [DOI] [PubMed]

70.

Chmiel KD, Suan D, Liddle C, Nankivell B, Ibrahim R, Bautista C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol. 2011;29:e237–40. [DOI] [PubMed]

71.

George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, et al. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis. Pancreatology. 2019;19:587–94. [DOI] [PubMed]

72.

Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, et al. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer. 2019;7:31. [DOI] [PubMed] [PMC]

73.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–68. [DOI] [PubMed] [PMC]

74.

Prasanna T, McNeil CM, Nielsen T, Parkin D. Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy. Immunotherapy. 2018;10:171–5. [DOI] [PubMed]